Annexon (ANNX) Interest Expenses (2019 - 2026)
Annexon (ANNX) posted quarterly Interest Expenses of $32.0 million for Q1 2026, up 129.1% year-over-year from $14.0 million in Q1 2025, and up 85.47% quarter-over-quarter from $17.2 million in Q4 2025.
Annexon (ANNX) Interest Expenses (2019 - 2026) Analysis & Trends
Annexon's Interest Expenses history runs 8 years deep, the most recent figure standing at $32.0 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 129.1% year-over-year to $32.0 million; the TTM figure through Mar 2026 stood at $32.0 million (up 129.1% YoY), while the FY2025 annual figure was $224.9 million, up 24.28% from the prior year.
- Interest Expenses for Q1 2026 stood at $32.0 million, up from $17.2 million in the prior quarter.
- The five-year high for Interest Expenses was $130.9 million in Q4 2023, with the low at $3.3 million in Q4 2022.
- The 5-year median for Interest Expenses is $32.0 million (2026), against an average of $32.7 million.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses jumped 3833.28% in 2023, then sank 96.9% in 2024.
- Annexon's Interest Expenses stood at $3.3 million in 2022, then surged by 3833.28% to $130.9 million in 2023, then tumbled by 96.9% to $4.1 million in 2024, then soared by 324.59% to $17.2 million in 2025, then jumped by 85.47% to $32.0 million in 2026.
- Business Quant data shows ANNX's Interest Expenses at $32.0 million in Q1 2026, $17.2 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 30.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.66 Mn |
| Jun 30, 2026 | 30.66 Mn |
| Mar 31, 2026 | 31.96 Mn |
| Mar 31, 2026 | 31.96 Mn |
| Dec 31, 2025 | 17.23 Mn |
| Dec 31, 2025 | 17.23 Mn |
| Sep 30, 2025 | 5.62 Mn |
| Sep 30, 2025 | 5.62 Mn |
| Jun 30, 2025 | 8.18 Mn |
| Jun 30, 2025 | 8.18 Mn |
| Mar 31, 2025 | 13.95 Mn |
| Mar 31, 2025 | 13.95 Mn |
| Dec 31, 2024 | 4.06 Mn |
| Dec 31, 2024 | 4.06 Mn |
| Sep 30, 2024 | 39.58 Mn |
| Sep 30, 2024 | 39.58 Mn |
| Jun 30, 2024 | 40.79 Mn |
| Jun 30, 2024 | 40.79 Mn |
| Mar 31, 2024 | 42.01 Mn |
| Mar 31, 2024 | 42.01 Mn |